Moxifloxacin
General properties
Antimicrobial agents for systemic use. Antimicrobial agents for systemic use. Carbapenems. Quinolone antibacterials. Fluoroquinolones. Moxifloxacin.
Treatment of the following bacterial infections cased by drug-sensitive microorganisms in patient aged 18 years and older:
– acute bacterial sinusitis (diagnosed with a high probability);
– exacerbations of chronic obstructive pulmonary disease, including bronchitis (diagnosed with a high probability);
– community-acquired pneumonia, except for severe course of community-acquired pneumonia.
– mild and moderate inflammatory diseases of pelvic organs (including infections of the upper part of female genital system, including salpingitis and endometritis), not associated with tubo-ovarian abscess or abscesses of the pelvic organs.
Moxifloxacin tablets may be used for the completion of the course of treatment, if the initial treatment with parenteral form of Moxifloxacin was effective and was administered for the following indications:
– community-acquired pneumonia;
– complicated skin and subcutaneous structures infections.
Moxifloxacin tablets are not recommended for the initial treatment of any skin and subcutaneous structures infections or with severe course of community-acquired pneumonia.
Known hypersensitivity to Moxifloxacin or any other quinolones group, or to any excepients of the drug;
– age under 18 years;
– pregnancy and lactation;
– previous history of tendon diseases associated with treatment with quinolones.
In the pre-clinical and clinical studies after moxifloxacin intake, changes in the heart electrophysiology were observed in the view of increasing the QT interval. Therefore for safety reasons the medication is contraindicated in patients with:
– congenital or diagnosed acquired increase of the QT interval;
– electrolytic balancedisorders, including uncorrected hypokalemia;
– clinically significant bradycardia;
– clinically significant heart failure with reduced ejection fraction of left ventricular;
– previous history of symptomatic arrhythmia.
The medication should not be concurrently used with drugs increasing QT interval.
Pharmaceutical characteristics
Coated tablets.
Store in the original packaging at temperature not exceeding 25 °C. Keep out of reach of children.
